A MOBILE app that essentially turns a smartphone into an easy-to-use, personal monitoring device for people with asthma, AsthmaSense? Cloud, has earned its creator and medical technology company, iSonea Limited the 2013 North American Frost & Sullivan Award for New Product Innovation Leadership.
The AsthmaSense mobile app turns a smartphone into an easy-to-use, personal monitoring device allowing people with asthma or caregivers to track medication usage, symptoms and triggers accurately.
The 2013 North American Frost & Sullivan Award for New Product Innovation Leadership acknowledges iSonea as a pioneer in the health care industry, specifically mHealth, for its development of body sensing devices that enable self-monitoring for specific health conditions like asthma.
"iSonea is both humbled and honored by this award," said Michael Thomas, iSonea chief executive officer. "To be recognized as a mHealth leader for AsthmaSense Cloud is a testament to the organization's unrelenting commitment to create and commercialize innovative asthma monitoring solutions."
Frost & Sullivan has more than 50 years of experience in working with Global 1000 companies, emerging businesses and the investment community. Each year, they present this award to a company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features of the product and the increased benefit it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.
The award will be presented to Thomas at the Frost & Sullivan 2013 Growth, Innovation and Leadership Summit in San Jose, California, on September 9.
According to Frost and Sullivan's industry analyst Vin Lee Nim, "In comparison to other competing solutions, adapting iSonea's asthma monitoring technology to the smartphone provides an easier and more convenient means of data collection, analysis and communication. AsthmaSense app and AsthmaSense Cloud's data compilation of users' asthma events clearly illustrate the 'cause and effect' by mapping the lifestyle, environmental and physiological causes of asthma attacks."
AsthmaSense serves many purposes in the tracking and management of chronic asthma, such as identifying potential risk patterns and trends in asthma symptoms; alerting the user when one should take medication and test his/her asthma risk; and creating a cloud-based network to share one's data with caregivers, physicians and more in a safe and reliable way.
iSonea Limited (ASX: ISN) (OTCQX: ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic RespiratorNike Air Max 90